Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Argenx Se ADR (NQ: ARGX )

394.63 -5.71 (-1.43%)
Streaming Delayed Price Updated: 1:59 PM EDT, Jun 7, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Argenx Se ADR

< Previous 1 2 3 4 5 Next >
Analyst Expectations for argenx's Future
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 31, 2023
 
Via Benzinga
Expert Ratings for argenx
 
Via Benzinga
argenx to Present at Upcoming Investor Conferences
From argenx SE
Via GlobeNewswire
Booking Holdings To Rally Around 18%? Here Are 10 Other Analyst Forecasts For Friday
Wells Fargo raised the price target for Royal Caribbean Cruises Ltd. (NYSE: RCL) from $78 to $88. Wells Fargo analyst Daniel Politzer maintained an Overweight rating. Royal Caribbean Cruises shares... 
Via Benzinga
Analyst Ratings for argenx
 
Via Benzinga
A Bearish Sign Appears On argenx's Chart
 
Via Benzinga
Analyst Ratings for argenx
 
Via Benzinga
argenx Reports First Quarter 2023 Financial Results and Provides Business Update
From argenx SE
Via GlobeNewswire
argenx announces results of Annual General Meeting of Shareholders
From argenx SE
Via GlobeNewswire
argenx to Present at BofA Securities 2023 Health Care Conference
From argenx SE
Via GlobeNewswire
argenx to Report First Quarter 2023 Financial Results and Business Update on May 4, 2023
From argenx SE
Via GlobeNewswire
Analyst Boosts Immunovant Price Target After Updated Pipeline Realignment
 
Via Benzinga
5 Analysts Have This to Say About argenx
 
Via Benzinga
Earnings Outlook For argenx
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 25, 2023
 
Via Benzinga
7 Biotech Stocks That Could Cure Your Portfolio Woes
If you want to revitalize your portfolio with some exciting opportunities, these biotech stocks to buy might fit the bill. 
Via InvestorPlace
argenx Demonstrates Commitment to Redefining Treatment Goals for Generalized Myasthenia Gravis with Multiple Presentations at American Academy of Neurology 2023 Annual Meeting
From argenx SE
Via GlobeNewswire
argenx and Genmab Enter Partnership to Advance Antibody Therapies in Immunology and Oncology
From argenx SE
Via GlobeNewswire
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
argenx Announces Annual General Meeting of Shareholders on May 2, 2023
From argenx SE
Via GlobeNewswire
argenx Announces UK MHRA Approval of VYVGART for the Treatment of Generalized Myasthenia Gravis
From argenx SE
Via GlobeNewswire
argenx Reports Full Year 2022 Financial Results and Provides Fourth Quarter Business Update
From argenx SE
Via GlobeNewswire
argenx Announces Planned Transition of Chief Operating Officer
From argenx SE
Via GlobeNewswire
argenx Appoints Steve Krognes to Board of Directors
From argenx SE
Via GlobeNewswire
argenx to Present at Upcoming Investor Conferences
From argenx SE
Via GlobeNewswire
argenx to Report Full Year 2022 Financial Results and Fourth Quarter Business Update on March 2, 2023
From argenx SE
Via GlobeNewswire
Immunovant Could Potentially Be An M&A Target, Writes Analyst
 
Via Benzinga
Here's What's Next For Biohaven After Its $12 Billion Pfizer Buyout, According To CEO Vlad Coric
The company that remains still has a large pipeline of non-migraine assets. 
Via Investor's Business Daily
argenx Receives Notification of PDUFA Date Extension for SC Efgartigimod
From argenx SE
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.